Leveraging on-table MR soft tissue imaging, MRIdian allows oncologists to visualize, adapt and target using diagnostic-quality anatomical detail that’s simply unavailable with conventional IGRT technologies.
Combining the latest innovations in precision radiation delivery, ground-breaking MR image guidance, and on-table adaptive therapy, MRIdian represents a new paradigm in radiation oncology.
ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its fourth quarter and full year 2018 financial results. ViewRay will hold a conference call to discuss results on Thursday March 14, 2019 at 4:30 p.m. ET / 1:30 p.m. PT.
World’s First MRIdian Center Celebrates Five Years of MRI-Guided Radiation Treatments
Siteman Cancer Center Advances Precision Cancer Care through Presentations, Peer-Reviewed Publications and Pioneering Clinical Experience on its MRIdian Systems
ViewRay Announces Preliminary Fourth Quarter and Fiscal Year 2018 Results
ViewRay, Inc. (Nasdaq: VRAY) today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2018. The preliminary results have not been audited and are subject to change.
A new kind of medical technology company—ViewRay® Inc. designs, manufactures and markets MRIdian, the world’s first MRI-Guided radiation therapy system to image and treat cancer patients simultaneously.
Contact Us Today To Learn More Contact
This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of our products and services, assist with our promotional and marketing efforts, and provide content from third parties. Cookie Policy